120 related articles for article (PubMed ID: 36378560)
1. Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer.
Ma LX; Espin-Garcia O; Bach Y; Aoyama H; Allen MJ; Wang X; Darling GE; Yeung J; Swallow CJ; Brar S; Veit-Haibach P; Kalimuthu S; Wong R; Chen EX; O'Kane GM; Jang RW; Elimova E
Oncologist; 2023 Mar; 28(3):214-219. PubMed ID: 36378560
[TBL] [Abstract][Full Text] [Related]
2. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer.
Minami S; Ihara S; Ikuta S; Komuta K
World J Oncol; 2019 Apr; 10(2):90-100. PubMed ID: 31068989
[TBL] [Abstract][Full Text] [Related]
3. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
[TBL] [Abstract][Full Text] [Related]
4. Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer Center.
Al Darazi G; Martin E; Delord JP; Korakis I; Betrian S; Estrabaut M; Poublanc M; Gomez-Roca C; Filleron T
Int J Cancer; 2021 May; 148(10):2502-2511. PubMed ID: 33231298
[TBL] [Abstract][Full Text] [Related]
5. Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer.
Minami S; Ihara S; Komuta K
World J Oncol; 2020 Jun; 11(3):98-105. PubMed ID: 32494316
[TBL] [Abstract][Full Text] [Related]
6. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
7. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.
Hahn AW; Alhalabi O; Msaouel P; Meric-Bernstam F; Naing A; Jonasch E; Piha-Paul S; Hong D; Pant S; Yap T; Campbell E; Le H; Tannir NM; Roszik J; Subbiah V
ESMO Open; 2020 Nov; 5(6):e001073. PubMed ID: 33229506
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Prognostic Scores in Early Phase Clinical Trials: A 10-year Single Centre Australian Experience.
Childs S; Nindra U; Yoon R; Haider S; Hong M; Roohullah A; Cooper A; Wilkinson K; Chua W; Pal A
Anticancer Res; 2024 May; 44(5):2095-2102. PubMed ID: 38677731
[TBL] [Abstract][Full Text] [Related]
9. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials.
Livingston JA; Hess KR; Naing A; Hong DS; Patel S; Benjamin RS; Ludwig JA; Conley A; Herzog CE; Anderson P; Meric-Bernstam F; Kurzrock R; Subbiah V
Oncotarget; 2016 Sep; 7(39):64421-64430. PubMed ID: 27486883
[TBL] [Abstract][Full Text] [Related]
10. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
11. Gustave Roussy Immune Score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable early-stage non-small-cell lung cancer: A propensity score matching retrospective cohort study.
Li SJ; Zhao L; Wang HY; Zhou HN; Ju J; Du H; Che GW
Int J Surg; 2020 Dec; 84():25-40. PubMed ID: 33086147
[TBL] [Abstract][Full Text] [Related]
12. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
13. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy.
Minichsdorfer C; Gleiss A; Aretin MB; Schmidinger M; Fuereder T
Ann Med; 2022 Dec; 54(1):1339-1349. PubMed ID: 35535695
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe: An Innovative Therapies for Children with Cancer study.
Carceller F; Bautista FJ; Jiménez I; Hladun-Álvaro R; Giraud C; Bergamaschi L; Dandapani M; Aerts I; Doz F; Frappaz D; Casanova M; Morland B; Hargrave DR; Marshall LV; Vassal G; Pearson AD; Geoerger B; Moreno L
Eur J Cancer; 2016 Nov; 67():130-140. PubMed ID: 27662616
[TBL] [Abstract][Full Text] [Related]
15. Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis.
Tian S; Cao Y; Duan Y; Liu Q; Peng P
Front Oncol; 2021; 11():737283. PubMed ID: 34917499
[TBL] [Abstract][Full Text] [Related]
16. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma.
Ma LX; Wang Y; Espin-Garcia O; Allen MJ; Jang GH; Zhang A; Dodd A; Ramotar S; Hutchinson S; Tehfe M; Ramjeesingh R; Biagi J; Wilson JM; Notta F; Fischer SE; Zogopoulos G; Gallinger S; Grant RC; Khokha R; Chan N; Grünwald BT; Knox JJ; O'Kane GM
Br J Cancer; 2023 May; 128(10):1916-1921. PubMed ID: 36927977
[TBL] [Abstract][Full Text] [Related]
17. Association of the Advanced Lung Cancer Inflammation Index (ALI) and Gustave Roussy Immune (GRIm) score with immune checkpoint inhibitor efficacy in patients with gastrointestinal and lung cancer.
Jiang H; Li B; Wu M; Wang Q; Li Y
BMC Cancer; 2024 Apr; 24(1):428. PubMed ID: 38589844
[TBL] [Abstract][Full Text] [Related]
18. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab.
Lenci E; Cantini L; Pecci F; Cognigni V; Agostinelli V; Mentrasti G; Lupi A; Ranallo N; Paoloni F; Rinaldi S; Nicolardi L; Caglio A; Aerts S; Cortellini A; Ficorella C; Chiari R; Di Maio M; Dingemans AC; Aerts JGJV; Berardi R
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801320
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of modified-Gustave-Roussy Immunity Score in resectable proximal gastric cancer.
Shi Y; Ju M; Di X; Sun X; Chen X; He C; Liang L
Medicine (Baltimore); 2023 Mar; 102(12):e33334. PubMed ID: 36961166
[TBL] [Abstract][Full Text] [Related]
20. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.
Maymani H; Hess K; Groisberg R; Hong DS; Naing A; Piha-Paul S; Janku F; Fu S; Tsimberidou AM; Pant S; Karp D; Liu S; Sun M; Heymach J; Simon G; Meric-Bernstam F; Subbiah V
Lung Cancer; 2018 Jun; 120():137-141. PubMed ID: 29748008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
